The FDA granted marketing clearance to Cytokinetics’ aficamten, branded Myqorzo, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The approval, announced Dec. 19 and detailed in company releases, authorizes multiple tablet strengths and includes prescribing warnings related to reduced left ventricular ejection fraction. Analysts and industry coverage note Myqorzo faces direct competition from Bristol Myers Squibb’s Camzyos; Cytokinetics argues its daily pill requires less intensive safety monitoring. The approval shifts the therapeutic landscape for oHCM by adding an oral myosin inhibitor with different clinical-management requirements. Clinicians and payers will watch postmarket uptake, labeling-driven monitoring pathways, and how prescribing patterns evolve against Camzyos, which has been a high-growth product for BMS. Regulatory-safety language and boxed warnings will shape adoption and risk-management programs.